An analysis of 15 name-brand drugs and their “skinny label” generic counterparts found that competition from these counterparts saved Medicare Part D nearly $15 billion from 2015 to 2021.
An analysis of 15 name-brand drugs and their “skinny label” generic counterparts found that competition from these counterparts saved Medicare Part D nearly $15 billion from 2015 to 2021.